News: added to Nasdaq Biotech IndexNeurochem Added to NASDAQ Biotech Index
11/13/03
MONTREAL, Nov 13, 2003 (Canada NewsWire via COMTEX) --
Neurochem Inc. (NASDAQ: NRMX, TSX: NRM) today announced that it has been selected to be added to the NASDAQ Biotechnology Index (NBI) effective on Monday, November 24, 2003. All securities in the Index are listed on the NASDAQ National Market and meet minimum re
quirements, including market value, average daily share volume and seasoning as a public company.
Launched in 1993, the NASDAQ Biotechnology Index consists of pharmaceutical and biotechnology companies as classified by the FTSE(TM) Global Classification System. The Index is ranked on a semi-annual basis in May and in November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund(SM) (IBB). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.
About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The Company's staged pipeline of proprietary, disease-modifying, oral products addresses critical unmet medical needs. Fibrillex(TM), designated an orphan drug, is in a Phase II/III clinical trial for AA amyloidosis. Alzhemed(TM) has completed a Phase II clinical trial for the treatment of Alzheimer's Disease. Cerebril(TM) is in a Phase II trial for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy. For additional information on Neurochem, please visit our website at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation as well as other risks included in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward- looking statements. The reader should not place undue reliance on the forward- looking statements included in this news release.